120 related articles for article (PubMed ID: 37452634)
21. JAK-STAT1 Signaling Pathway Is an Early Response to
Li X; Pan K; Vieth M; Gerhard M; Li W; Mejías-Luque R
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35456965
[No Abstract] [Full Text] [Related]
22. SRRM1 promotes the proliferation, migration, and invasion of hepatocellular carcinoma cells by regulating the JAK/STAT signaling pathway.
Song X; Ma J
Tissue Cell; 2022 Dec; 79():101954. PubMed ID: 36270072
[TBL] [Abstract][Full Text] [Related]
23. JAK2 and PD-L1 Amplification Enhance the Dynamic Expression of PD-L1 in Triple-negative Breast Cancer.
Chen M; Pockaj B; Andreozzi M; Barrett MT; Krishna S; Eaton S; Niu R; Anderson KS
Clin Breast Cancer; 2018 Oct; 18(5):e1205-e1215. PubMed ID: 29933930
[TBL] [Abstract][Full Text] [Related]
24. Long non-coding RNA HOTTIP enhances IL-6 expression to potentiate immune escape of ovarian cancer cells by upregulating the expression of PD-L1 in neutrophils.
Shang A; Wang W; Gu C; Chen C; Zeng B; Yang Y; Ji P; Sun J; Wu J; Lu W; Sun Z; Li D
J Exp Clin Cancer Res; 2019 Sep; 38(1):411. PubMed ID: 31533774
[TBL] [Abstract][Full Text] [Related]
25. FRZB is Regulated by the Transcription Factor EGR1 and Inhibits the Growth and Invasion of Triple-Negative Breast Cancer Cells by Regulating the JAK/STAT3 Pathway.
Liu H; Mei Y; Ma X; Zhang X; Nie W
Clin Breast Cancer; 2022 Oct; 22(7):690-698. PubMed ID: 35787980
[TBL] [Abstract][Full Text] [Related]
26. Atezolizumab and blockade of LncRNA PVT1 attenuate cisplatin resistant ovarian cancer cells progression synergistically via JAK2/STAT3/PD-L1 pathway.
Chen Y; Li F; Li D; Liu W; Zhang L
Clin Immunol; 2021 Jun; 227():108728. PubMed ID: 33878452
[TBL] [Abstract][Full Text] [Related]
27. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
28. Immunoblotting Analysis of Intracellular PD-L1 Levels in Interferon-γ-Treated Ovarian Cancer Cells Stably Transfected with Bcl3 shRNA.
Padmanabhan S; Zou Y; Vancurova I
Methods Mol Biol; 2020; 2108():211-220. PubMed ID: 31939183
[TBL] [Abstract][Full Text] [Related]
29. MicroRNA-375 reverses the expression of PD-L1 by inactivating the JAK2/STAT3 signaling pathways in gastric cancer.
Yan XL; Luo QY; Zhou SN; Pan WT; Zhang L; Yang DJ; Qiu MZ
Clin Res Hepatol Gastroenterol; 2021 Sep; 45(5):101574. PubMed ID: 33272890
[TBL] [Abstract][Full Text] [Related]
30. MiR-198 affects the proliferation and apoptosis of colorectal cancer through regulation of ADAM28/JAK-STAT signaling pathway.
Li LX; Lam IH; Liang FF; Yi SP; Ye LF; Wang JT; Guo WW; Xu M
Eur Rev Med Pharmacol Sci; 2019 Feb; 23(4):1487-1493. PubMed ID: 30840270
[TBL] [Abstract][Full Text] [Related]
31. MiR-92 overexpression suppresses immune cell function in ovarian cancer via LATS2/YAP1/PD-L1 pathway.
Feng S; Sun H; Zhu W
Clin Transl Oncol; 2021 Mar; 23(3):450-458. PubMed ID: 32654106
[TBL] [Abstract][Full Text] [Related]
32. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
33. STAT1/IFIT2 signaling pathway is involved in PD-L1-mediated epithelial-to-mesenchymal transition in human esophageal cancer.
Chen J; Liu Y; Zhu Y; Chen Y; Feng J; Jiang T; Zheng X; Chen L; Jiang J
Clin Transl Oncol; 2022 May; 24(5):927-940. PubMed ID: 35107757
[TBL] [Abstract][Full Text] [Related]
34. The proto-oncogene Bcl3 induces immune checkpoint PD-L1 expression, mediating proliferation of ovarian cancer cells.
Zou Y; Uddin MM; Padmanabhan S; Zhu Y; Bu P; Vancura A; Vancurova I
J Biol Chem; 2018 Oct; 293(40):15483-15496. PubMed ID: 30135206
[TBL] [Abstract][Full Text] [Related]
35. Expression of STAT1 is positively correlated with PD-L1 in human ovarian cancer.
Liu F; Liu J; Zhang J; Shi J; Gui L; Xu G
Cancer Biol Ther; 2020 Oct; 21(10):963-971. PubMed ID: 33043814
[TBL] [Abstract][Full Text] [Related]
36. Ginsenoside Rh4 inhibits breast cancer growth through targeting histone deacetylase 2 to regulate immune microenvironment and apoptosis.
Dong F; Qu L; Duan Z; He Y; Ma X; Fan D
Bioorg Chem; 2023 Jun; 135():106537. PubMed ID: 37043883
[TBL] [Abstract][Full Text] [Related]
37. Genetic analysis of cancer drivers reveals cohesin and CTCF as suppressors of PD-L1.
Oreskovic E; Wheeler EC; Mengwasser KE; Fujimura E; Martin TD; Tothova Z; Elledge SJ
Proc Natl Acad Sci U S A; 2022 Feb; 119(7):. PubMed ID: 35149558
[TBL] [Abstract][Full Text] [Related]
38. The Polyhomeotic protein induces hyperplastic tissue overgrowth through the activation of the JAK/STAT pathway.
González I; Simón R; Busturia A
Cell Cycle; 2009 Dec; 8(24):4103-11. PubMed ID: 19923887
[TBL] [Abstract][Full Text] [Related]
39. CNOT7 modulates biological functions of ovarian cancer cells via AKT signaling pathway.
Yu J; Hu X; Chen X; Zhou Q; Jiang Q; Shi Z; Zhu H
Life Sci; 2021 Mar; 268():118996. PubMed ID: 33412213
[TBL] [Abstract][Full Text] [Related]
40. PD-L1 induced by IFN-γ from tumor-associated macrophages via the JAK/STAT3 and PI3K/AKT signaling pathways promoted progression of lung cancer.
Zhang X; Zeng Y; Qu Q; Zhu J; Liu Z; Ning W; Zeng H; Zhang N; Du W; Chen C; Huang JA
Int J Clin Oncol; 2017 Dec; 22(6):1026-1033. PubMed ID: 28748356
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
